Xencor, Inc. (XNCR)
XNCRNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$37.09
-1.04 (-2.73%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $2.78bn
- P/E
- –
- EPS, last 4 quarters
- $-1.59
- Dividend yield
- –
- Day range
- –
- 52-week range
- $10.38 to $40.60
- Average volume
- –
- Previous close
- $38.13
Analysts
11 coveringBuy9 buy, 2 hold, 0 sell
Targets a year out average $41.11, +10.8% from here
Earnings
next estimate $-0.9400Next report
Dec 2025
+85.9%
Mar 2026
-163.1%
Jun 2026
+64.6%
Sep 2026
+242.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $28.24m | $4.52m | $51.22m | $116.52m |
| Gross profit | $28.24m | $4.52m | $51.22m | $116.52m |
| Operating income | -$53.63m | -$77.86m | -$37.07m | $22.86m |
| Net income | -$6.65m | -$128.92m | -$21.73m | $39.44m |
Last four quarters: revenue $200.49m, margin -58.8%, free cash flow -$176.45m
News
8 latest- Show Me The Money: Xencor (XNCR) Delivers Triple-Digit Gains, With XENITH-UC Poised For The Next Act RTTNews · Nov 6, 2026
- Xencor, Inc. Reports Third Quarter 2026 Financial Results and Outlines Clinical Pipeline PlansFintel · Nov 4, 2026
- Xencor (XNCR) Q3 Earnings and Revenues Beat EstimatesZacks · Nov 4, 2026
- Xencor Consensus Price Target Increased by 34.27% to $44.32Fintel · Nov 2, 2026
- Three Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD Readout RTTNews · Oct 26, 2026
- Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney CancerMarketBeat · Oct 26, 2026
- Xencor, Inc. Selects 400 mcg/kg as Proposed Recommended Phase 3 Dose for XmAb819 in Advanced Clear Cell Renal Cell CarcinomaFintel · Oct 26, 2026
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.The Motley Fool · Aug 31, 2026
The company
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- xencor.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.